Resolving the Lomustine Crisis for Glioblastoma Patients
According to the Society for Neuro-Oncology, “the field of neuro-oncology is in the midst of a crisis with lomustine.” Recently, the sole foreign-sourced manufacturer of lomustine significantly increased the price of the drug, making clinical trials cost-prohibitive. In 2021, the manufacturer pulled out of the federal discount program for Medicare patients, leaving many patients struggling to pay for treatment. The APIIC is working in partnership with Continuity Pharma and the Glioblastoma Foundation to resolve the lomustine crisis utilizing the advanced technologies of continuous flow manufacturing.
What we’ve done
The APIIC has brought together over 10 partners for the U.S. production of lomustine to:
- Create a sustainable supply for patient treatment
- Reduce the cost of the drug
- Enable new drug clinical trials
get in touch
Contact the Center
For more information about the Center and its work to de-risk the return of API production back to the U.S., contact us today.